Frequency, Phenotype, Outcome and Therapeutic Impact of Skin Reactions Following Initiation of Adalimumab Therapy: Experience From a Consecutive Cohort of Inflammatory Bowel Disease Patients

Frequency, phenotype, outcome, and thera

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients

✍ Daniel C. Baumgart; Ulrike Grittner; Andrea Steingräber; Marina Azzaro; Sandra P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

## Background: The monoclonal anti tumor necrosis factor (TNF) antibody adalimumab has recently been approved for Crohn's disease (CD) and evaluated for ulcerative colitis (UC). Cutaneous lesions associated with its administration have not been prospectively studied in inflammatory bowel disease (